Ocugen Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $4.6M+13.0% YoYTTM through 30 Jun 2026
Net Income -$81.8MTTM through 30 Jun 2026
Free Cash Flow -$61MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Operating Margin | -1,165.5% |
| Net Margin | -1,785.9% |
Returns
-126.0%ROA
Balance Sheet Health
Debt / Equity5.03x
Current Ratio1.86x
Net Debt-$2.7Mnet cash position
Cash & Equivalents$100.1M
Quality Metrics
Altman Z-Score-5.64
Piotroski F-Score4 / 9
FCF Margin-1,332.1%
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $4.4M
Diluted EPSFY2023: $-0.26
Dividend
No dividend
Capital Allocation
Capex Intensity3.3%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Collaborative Arrangements | $1.5M | +3.5% | View detailsOcugen continues to pursue regional partnerships, such as the exclusive licensing agreement with Kwangdong Pharmaceutical for OCU400 in South Korea. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.